Overview

Double-blind Comparative Study of SYR-472

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Alogliptin